$8.8 Million Awarded to Penn Alzheimer's Disease Center in NIH Funding

by Dr. Trupti Shirole on  August 3, 2016 at 6:06 PM Research News   - G J E 4
Alzheimer's disease is the most common form of dementia. It causes problems with memory and other intellectual abilities serious enough to interfere with daily life. The University of Pennsylvania's Alzheimer's Disease Core Center (ADCC) has been awarded an estimated $8.8 million over five years from the National Institute on Aging (NIA) to continue its mission of investigating mechanisms, diagnostics, treatments and strategies for Alzheimer's Disease (AD) and related dementias including Parkinson's disease (PD), Parkinson's disease dementia (PDD), Lewy Body dementia (LBD) and frontotemporal lobar degeneration (FTLD).
 $8.8 Million Awarded to Penn Alzheimer's Disease Center in NIH Funding
$8.8 Million Awarded to Penn Alzheimer's Disease Center in NIH Funding

Discoveries from Penn's ADCC have advanced understanding of the development and progression of AD and related neurodegenerative dementias over the past 25 years, leading to national and international recognition of its research accomplishments.

‘The University of Pennsylvania's Alzheimer's Disease Core Center (ADCC) has been awarded $8.8 million from the National Institute on Aging (NIA) to continue the study for Alzheimer's Disease (AD) and related dementias.’
"This funding will allow us to build on these successes," said John Q. Trojanowski, the William Maul Measey-Truman G. Schnabel, Professor of Geriatric Medicine and Gerontology and a professor of Pathology and Laboratory Medicine in the Perelman School of Medicine and founding director of the Penn ADCC.

The renewal funding will take the Penn ADCC through year 30 and support the Center's efforts to recruit, follow and study subjects with AD, especially at their earliest stage, as well as study healthy subjects, with a special emphasis on the African-American population. The funding will also enhance the center's bioinformatics infrastructure to better integrate different types of data, as well as expand banks for central nervous system (CNS) tissues, DNA and biofluids for diagnostic studies to better understand AD mechanisms. Finally, these funds will expand the Penn ADCC's commitment to educating the next generation of dementia researchers.

The Penn ADCC has a history of groundbreaking discoveries. For example, researchers at Penn were the first to discover the protein tau as the building blocks of neurofibrillary tangles, one of the two hallmark brain lesions that cause AD. Their research also showed that Lewy bodies in PD, PDD and LBD and 50 percent of AD patients are formed by the protein alpha-synuclein. They also discovered the protein TDP-43 as the genesis for the inclusions in FTLD and amyotrophic lateral sclerosis (ALS), and in 50% of AD patients. These discoveries provided new information about the pathology of AD and showed that therapies to treat AD would likely need to target the AD plaques and tangles that define the disease, as well as alpha-synuclein and TDP-43 pathologies which also are associated with cognitive impairments. In addition, the Penn ADCC contributed to defining biomarkers for early stage AD that have improved the conduct of AD clinical trials, increased the diversity of ADCC study populations, clarified ethical issues related to disclosing sensitive genetic and other diagnostic information to patients, and conducted clinical trials of therapies to prevent or slow AD progression.

Trojanowski and his collaborators lead the ADCC's six areas of research and clinical operations, known as "cores." These leaders include Murray Grossman, professor of Neurology; Jason Karlawish, professor of Medicine, Medical Ethics and Health Policy and co-associate director of the ADCC; Eddie Lee, assistant professor of Pathology and Laboratory Medicine; Virginia Lee, John H. Ware 3rd Endowed Professor in Alzheimer's Research; Vivianna Van Deerlin, professor of Pathology and Laboratory Medicine; Li-San Wang, associate professor of Pathology and Laboratory Medicine; David Wolk, associate professor of Neurology and co-associate director of the ADCC; and Sharon Xie, professor of Biostatistics in the department of Biostatistics and Epidemiology. These faculty come from five different departments in the Perelman School of Medicine, which reflects the increasingly multi-disciplinary nature of research on AD and related dementias.

"We are pleased to renew our support for the Penn ADC so that it may continue contributing to our national effort to end the devastation wrought by Alzheimer's and related dementias," said Nina Silverberg, an Alzheimer's Disease Centers program director at the National Institute on Aging, part of NIH. "We are hopeful our support for the Penn ADC research program will lead to novel findings on the basic mechanisms involved in these diseases, and innovative new programs aimed at improving the lives of those living with dementia and their caregivers."

The Alzheimer's Disease Centers (ADC) program was launched by the NIA in 1984 to establish a broad-based research effort at a time when aging and AD research languished behind more established scientific disciplines. The program was expanded in 1990, leading to the creation of Penn's ADCC in 1991. There are currently 29 ADCs in total and the Penn ADCC is regarded as exceptional for the extent to which it collaborates with other ADCs and focuses on AD and related dementias.

"The creation of ADCs marked the beginning of the recognition of AD and related disorders by the NIH," Trojanowski said. "Through the ADCs, the NIH has served as a champion for the development of potential treatments as the incidence of AD and related dementias are on the rise."

"The continued support of the NIA allows us to keep our foot on the gas in the hopes that scientific discovery will lead to clinical trials and treatments for this devastating set of diseases," he added.

Penn Medicine is one of the world's leading academic medical centers, dedicated to the related missions of medical education, biomedical research, and excellence in patient care. Penn Medicine consists of the Raymond and Ruth Perelman School of Medicine at the University of Pennsylvania (founded in 1765 as the nation's first medical school) and the University of Pennsylvania Health System, which together form a $5.3 billion enterprise.

The Perelman School of Medicine has been ranked among the top five medical schools in the United States for the past 18 years, according to U.S. News & World Report's survey of research-oriented medical schools. The School is consistently among the nation's top recipients of funding from the National Institutes of Health, with $373 million awarded in the 2015 fiscal year.

The University of Pennsylvania Health System's patient care facilities include: The Hospital of the University of Pennsylvania and Penn Presbyterian Medical Center - which are recognized as one of the nation''s top "Honor Roll" hospitals by U.S. News & World Report - Chester County Hospital; Lancaster General Health; Penn Wissahickon Hospice; and Pennsylvania Hospital - the nation's first hospital, founded in 1751. Additional affiliated inpatient care facilities and services throughout the Philadelphia region include Chestnut Hill Hospital and Good Shepherd Penn Partners, a partnership between Good Shepherd Rehabilitation Network and Penn Medicine.

Penn Medicine is committed to improving lives and health through a variety of community-based programs and activities. In fiscal year 2015, Penn Medicine provided $253.3 million to benefit our community.

Source: Newswise

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
Notify me when reply is posted I agree to the terms and conditions

You May Also Like

View All